loading page

The effects of astaxanthin supplementation on the expression of miR-146a and miR-126, oxidative stress and inflammation in patients with type 2 diabetes mellitus: A randomized double blind placebo controlled clinical trial
  • +3
  • Amirhossein farokhzad,
  • Nafiseh Sokri Mashhadi,
  • Maryam Tahmasebi,
  • Javad Mohammadi-asl,
  • Mehrnoosh Zakerkish,
  • Majid Mohammadshahi
Amirhossein farokhzad

Corresponding Author:[email protected]

Author Profile
Nafiseh Sokri Mashhadi
Isfahan University of Medical Sciences
Author Profile
Maryam Tahmasebi
Ahvaz Jondishapour University of Medical Sciences
Author Profile
Javad Mohammadi-asl
Ahvaz Jondishapour University of Medical Sciences
Author Profile
Mehrnoosh Zakerkish
Ahvaz Jondishapour University of Medical Sciences
Author Profile
Majid Mohammadshahi
Ahvaz Jondishapour University of Medical Sciences
Author Profile

Abstract

Background: The pathogenesis of type 2 diabetes (T2D) is associated with chronic oxidative stress and inflammation. It is well known that the expression of some miRNAs such as miRNA-146a up- regulate in diabetic and hyperglycemic patients whereas, circulating miRNA-126 reduces. Therefore, the purpose of this study was to determinate the effects of Astaxanthin supplementation on the expression of miR-146a and miR-126, MDA and inflammation in patients with type 2 diabetes. Methods: This randomized double-blind placebo-controlled clinical trial was conducted on 44 type 2 diabetes patients who were randomly assigned to received 8mg of oral Astaxanthin/d (n=22) or placebo(n=22) for 8 weeks. Results: We observed that Astaxanthin supplementation could decrease plasma levels of MDA and IL-6 (P < 0.05) and declined the expression level of miR-146a over time (Fold change: -1/388) (P < 0.05). Conclusion: Astaxanthin supplementation might be beneficial for improving circulating MDA and IL-6 and down regulation of miR-146a. However, future investigations are suggested to confirm these results.
07 Sep 2020Submitted to International Journal of Clinical Practice
15 Sep 2020Submission Checks Completed
15 Sep 2020Assigned to Editor
16 Sep 2020Reviewer(s) Assigned
08 Oct 2020Review(s) Completed, Editorial Evaluation Pending
18 Nov 20201st Revision Received
20 Nov 2020Reviewer(s) Assigned
20 Nov 2020Submission Checks Completed
20 Nov 2020Assigned to Editor
27 Nov 2020Review(s) Completed, Editorial Evaluation Pending
26 Dec 20202nd Revision Received
28 Dec 2020Submission Checks Completed
28 Dec 2020Assigned to Editor
28 Dec 2020Reviewer(s) Assigned
07 Jan 2021Review(s) Completed, Editorial Evaluation Pending
11 Jan 2021Editorial Decision: Accept